Mustang Bio Inc (NASDAQ:MBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Mustang Bio Inc (MBIO)
Mustang Bio Inc (NASDAQ:MBIO) has a market capitalization of $3.37 Million ($3.37 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29369 globally and #5999 in its home market, demonstrating a -7.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Mustang Bio Inc's stock price $0.50 by its total outstanding shares 6732121 (6.73 Million). Also see MBIO asset base for a full breakdown of the balance sheet.
Mustang Bio Inc Market Cap History: 2017 to 2026
Mustang Bio Inc's market capitalization history from 2017 to 2026. Data shows change from $1.21 Billion to $3.30 Million (-46.55% CAGR). Also see Mustang Bio Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Mustang Bio Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #853 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #2734 of 3165 |
Weight: Mustang Bio Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Mustang Bio Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Mustang Bio Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check MBIO stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MBIO by Market Capitalization
Companies near Mustang Bio Inc in the global market cap rankings as of September 18, 2026. Review Mustang Bio Inc (MBIO) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Mustang Bio Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Mustang Bio Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Mustang Bio Inc's market cap moved from $1.21 Billion to $ 3.30 Million, with a yearly change of -46.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.30 Million | -50.05% |
| 2025 | $6.60 Million | +454.24% |
| 2024 | $1.19 Million | -86.89% |
| 2023 | $9.09 Million | -77.21% |
| 2022 | $39.88 Million | -76.21% |
| 2021 | $167.63 Million | -56.14% |
| 2020 | $382.22 Million | -7.23% |
| 2019 | $412.01 Million | +38.78% |
| 2018 | $296.89 Million | -75.48% |
| 2017 | $1.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Mustang Bio Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.37 Million USD |
| MoneyControl | $3.37 Million USD |
| MarketWatch | $3.37 Million USD |
| marketcap.company | $3.37 Million USD |
| Reuters | $3.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB… Read more